Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2015

View Archived Issues

Valeant to acquire Commonwealth Laboratories' business in U.S. and Canada

Scynexis sells services business, focuses on SCY-078

Novel orally active Chk1 inhibitor boosts combination therapies for lung and pancreatic cancer

Gene therapy with viral vectors carrying Tmc genes, a promising approach for genetic deafness

Caladrius Biosciences secures NIH grant to develop 3D retinal cell implants

Bone marrow-derived mesenchymal stromal cell therapy beneficial in severe ischemic heart failure

Therapure Biopharma receives funding for manufacture of plasma proteins

Astellas partners with AIST in virtual drug discovery

FDA grants orphan drug designation to Ziopharm's Ad-RTS-hIL-12 + veledimex for malignant glioma

Bristol-Myers Squibb offers overview of second quarter 2015

World Hepatitis Day 2015: New management recommendations and new treatments

EMA grants accelerated assessment to MAA for elotuzumab in MM

Medivation discloses TGF-beta signaling inhibitors

Rhizen patents glutaminase inhibitors

Bristol-Myers Squibb introduces ROR-gamma modulators

Purdue Pharma divulges morphinan analgesics

Beijing Institute of Pharmacology and Toxicology discloses new analgesics

TapImmune exercises option agreement for folate receptor alpha vaccine technology

Alnylam starts phase I/II trial of RNAi targeting alpha-1 antitrypsin

Teva to acquire Allergan generics; withdraws offer for Mylan

Epratuzumab misses primary endpoints in two phase III SLE trials

Clinical benefit seen with trofinetide in phase II Rett's syndrome study

FDA clears FibroGen to begin phase II trial of FG-3019 for DMD

EMA committee recommends approval of Cresemba for invasive aspergillosis and mucormycosis

Obizur recommended for approval in Europe for acquired hemophilia A

EMA committee hands down positive opinion for Zerbaxa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...